Anti-FGFR1抗体(ab10646)
Key features and details
- Rabbit polyclonal to FGFR1
- Suitable for: IHC-P, WB, ICC/IF
- Reacts with: Human
- Isotype: IgG
选择批间可重复性更高的重组抗体
- 研究可靠 —— 各批次间结果一致且可重复
- 长期批量供应 —— 采用重组技术，可实现快速生产
- 首次实验即可成功 —— 经过大量验证确认了特异性
- 符合伦理标准 —— 产品不含动物成分
概述
-
产品名称
Anti-FGFR1抗体
参阅全部 FGFR1 一抗 -
描述
兔多克隆抗体to FGFR1 -
宿主
Rabbit -
特异性
ab10646 does not react with human FGFR2 and FGFR3. -
经测试应用
适用于: IHC-P, WB, ICC/IFmore details -
种属反应性
与反应: Human -
免疫原
Synthetic peptide corresponding to Human FGFR1 aa 360-373 conjugated to keyhole limpet haemocyanin. With a C-terminal added lysine.
Sequence:EALEERPAVMTSPLK
Database link: P11362 -
常规说明
Fibroblast growth factors (FGFs) are members of a large family of structurally related polypeptides (17-38 kDa) that are potent physiological regulators of growth and differentiation of a wide variety of cells of mesodermal, ectodermal and endodermal origin. FGFs are substantially involved in normal development, wound healing and repair, angiogenesis, a variety of neurotrophic activities, in hematopoiesis as well as in tissue remodeling and maintenance. They also have been implicated in pathological conditions such as tumorigenesis and metastasis. To date, the FGF family consists of at least 23 members designated FGF1 through FGF23. Four genes encoding for high affinity cell surface FGF receptors (FGFRs) have been identified: FGFR1 [flg-1(fms-like gene 1)]; FGFR2 [bek (bacterial expressed kinase gene product)]; FGFR3 (cek-2), and FGFR4. Multiple additional variants (isoforms) arising by alternative splicing have been reported: soluble, secreted, or possibly cleaved forms of FGFR1 and FGFR2 have also been found in body fluids or were artificially constructed, [e.g. a soluble FGF-binding protein containing the extracellular region of FGFR1 and the secreted form of placental alkaline phosphatase (FRAP1)]. FGFRs are members of the tyrosine kinase family of growth factor receptors. They are glycosylated 110- 150 kDa proteins that are constructed of an extracellular ligand binding region with either two (alpha type) or typically three (alpha type) immunoglbulin (Ig)-like domains and an eight amino acid acidic box, a transmembrane region, and a cytoplasmic split tyrosine kinase domain that is activated following ligand binding and receptor dimerization. The ligand binding site of FGFRs is confined to the extracellular Ig-like domains 2 and 3. FGFRs exhibit overlapping recognition and redundant specificity. One receptor type may bind with a similar affinity several of the FGFs. Also one FGF type may bind similarly to several distinct receptors. This accounts for the rather identical effects of different FGF ligands on common cell types. FGF’s binding to cellular FGFRs depend on or is markedly facilitated by the low-affinity interaction of FGF with the polysaccharide component of the cell surface or extracellular matrix heparan sulfate proteoglycans (HSPG). For example, perlecan, a basement membrane HSPG, promotes high affinity binding of FGF2 in vitro and angiogenesis in vivo. Signal transduction by FGFRs requires dimerization or oligomerization and autophosphorylation of the receptors through their tyrosine kinase domain. Subsequent association with cytoplasmic signaling molecules leads to DNA synthesis or differentiation. The signaling and biological responses elicited by distinct FGFRs substantially differ and are dictated by the intracellular domain. At the mRNA level, FGFR1 is highly expressed in developing human tissues including the brain (preferentially in neurons), vascular basement membranes, skin, and bone growth plates. It may be found in most anchorage dependent cells on their membrane and also may be localized around and in nuclei. Pfeiffer syndrome, as well as other disorders of human skeletal development, is the result of a mutation in the extracellular domain of FGFR1.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
性能
-
形式
Liquid -
存放说明
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
存储溶液
pH: 7.40
Preservative: 0.097% Sodium azide
Constituents: PBS, 1% BSA -
Concentration information loading... -
纯度
Immunogen affinity purified -
纯化说明
The product is an affinity-purified antibody prepared from pooled sera. -
Primary antibody说明
Fibroblast growth factors (FGFs) are members of a large family of structurally related polypeptides (17-38 kDa) that are potent physiological regulators of growth and differentiation of a wide variety of cells of mesodermal, ectodermal and endodermal origin. FGFs are substantially involved in normal development, wound healing and repair, angiogenesis, a variety of neurotrophic activities, in hematopoiesis as well as in tissue remodeling and maintenance. They also have been implicated in pathological conditions such as tumorigenesis and metastasis. To date, the FGF family consists of at least 23 members designated FGF1 through FGF23. Four genes encoding for high affinity cell surface FGF receptors (FGFRs) have been identified: FGFR1 [flg-1(fms-like gene 1)]; FGFR2 [bek (bacterial expressed kinase gene product)]; FGFR3 (cek-2), and FGFR4. Multiple additional variants (isoforms) arising by alternative splicing have been reported: soluble, secreted, or possibly cleaved forms of FGFR1 and FGFR2 have also been found in body fluids or were artificially constructed, [e.g. a soluble FGF-binding protein containing the extracellular region of FGFR1 and the secreted form of placental alkaline phosphatase (FRAP1)]. FGFRs are members of the tyrosine kinase family of growth factor receptors. They are glycosylated 110- 150 kDa proteins that are constructed of an extracellular ligand binding region with either two (alpha type) or typically three (alpha type) immunoglbulin (Ig)-like domains and an eight amino acid acidic box, a transmembrane region, and a cytoplasmic split tyrosine kinase domain that is activated following ligand binding and receptor dimerization. The ligand binding site of FGFRs is confined to the extracellular Ig-like domains 2 and 3. FGFRs exhibit overlapping recognition and redundant specificity. One receptor type may bind with a similar affinity several of the FGFs. Also one FGF type may bind similarly to several distinct receptors. This accounts for the rather identical effects of different FGF ligands on common cell types. FGF’s binding to cellular FGFRs depend on or is markedly facilitated by the low-affinity interaction of FGF with the polysaccharide component of the cell surface or extracellular matrix heparan sulfate proteoglycans (HSPG). For example, perlecan, a basement membrane HSPG, promotes high affinity binding of FGF2 in vitro and angiogenesis in vivo. Signal transduction by FGFRs requires dimerization or oligomerization and autophosphorylation of the receptors through their tyrosine kinase domain. Subsequent association with cytoplasmic signaling molecules leads to DNA synthesis or differentiation. The signaling and biological responses elicited by distinct FGFRs substantially differ and are dictated by the intracellular domain. At the mRNA level, FGFR1 is highly expressed in developing human tissues including the brain (preferentially in neurons), vascular basement membranes, skin, and bone growth plates. It may be found in most anchorage dependent cells on their membrane and also may be localized around and in nuclei. Pfeiffer syndrome, as well as other disorders of human skeletal development, is the result of a mutation in the extracellular domain of FGFR1. -
克隆
多克隆 -
同种型
IgG -
研究领域
相关产品
-
ChIP Related Products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
应用
The Abpromise guarantee
Abpromise™承诺保证使用ab10646于以下的经测试应用
“应用说明”部分 下显示的仅为推荐的起始稀释度；实际最佳的稀释度/浓度应由使用者检定。
| 应用 | Ab评论 | 说明 |
|---|---|---|
| IHC-P |
1/200. Perform enzymatic antigen retrieval before commencing with IHC staining protocol.
The epitopes recognized by the antibody are resistant to routine formalin-fixation and paraffin embedding, and to other fixatives e.g. Methacarn, Bouins solution, ethanol and B5. |
|
| WB | (1) |
1/400. This was determined by blotting using an extract of FGFR-1 transfected cells.
|
| ICC/IF | (1) |
1/200.
|
| 说明 |
|---|
|
IHC-P
1/200. Perform enzymatic antigen retrieval before commencing with IHC staining protocol. The epitopes recognized by the antibody are resistant to routine formalin-fixation and paraffin embedding, and to other fixatives e.g. Methacarn, Bouins solution, ethanol and B5. |
|
WB
1/400. This was determined by blotting using an extract of FGFR-1 transfected cells. |
|
ICC/IF
1/200. |
靶标
-
功能
Receptor for basic fibroblast growth factor. Receptor for FGF23 in the presence of KL (By similarity). A shorter form of the receptor could be a receptor for FGF1 (aFGF). -
组织特异性
Detected in astrocytoma, neuroblastoma and adrenal cortex cell lines. Some isoforms are detected in foreskin fibroblast cell lines, however isoform 17, isoform 18 and isoform 19 are not detected in these cells. -
疾病相关
Defects in FGFR1 are a cause of Pfeiffer syndrome (PS) [MIM:101600]; also known as acrocephalosyndactyly type V (ACS5). PS is characterized by craniosynostosis (premature fusion of the skull sutures) with deviation and enlargement of the thumbs and great toes, brachymesophalangy, with phalangeal ankylosis and a varying degree of soft tissue syndactyly.
Defects in FGFR1 are a cause of idiopathic hypogonadotropic hypogonadism (IHH) [MIM:146110]. IHH is defined as a deficiency of the pituitary secretion of follicle-stimulating hormone and luteinizing hormone, which results in the impairment of pubertal maturation and of reproductive function.
Defects in FGFR1 are the cause of Kallmann syndrome type 2 (KAL2) [MIM:147950]; also known as hypogonadotropic hypogonadism and anosmia. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In some cases, midline cranial anomalies (cleft lip/palate and imperfect fusion) are present and anosmia may be absent or inconspicuous.
Defects in FGFR1 are the cause of osteoglophonic dysplasia (OGD) [MIM:166250]; also known as osteoglophonic dwarfism. OGD is characterized by craniosynostosis, prominent supraorbital ridge, and depressed nasal bridge, as well as by rhizomelic dwarfism and nonossifying bone lesions. Inheritance is autosomal dominant.
Defects in FGFR1 are the cause of trigonocephaly non-syndromic (TRICEPH) [MIM:190440]; also known as metopic craniosynostosis. The term trigonocephaly describes the typical keel-shaped deformation of the forehead resulting from premature fusion of the frontal suture. Trigonocephaly may occur also as a part of a syndrome.
Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell leukemia lymphoma syndrome (SCLL). Translocation t(8;13)(p11;q12) with ZMYM2. SCLL usually presents as lymphoblastic lymphoma in association with a myeloproliferative disorder, often accompanied by pronounced peripheral eosinophilia and/or prominent eosinophilic infiltrates in the affected bone marrow.
Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell myeloproliferative disorder (MPD). Translocation t(6;8)(q27;p11) with FGFR1OP. Insertion ins(12;8)(p11;p11p22) with FGFR1OP2. MPD is characterized by myeloid hyperplasia, eosinophilia and T-cell or B-cell lymphoblastic lymphoma. In general it progresses to acute myeloid leukemia. The fusion proteins FGFR1OP2-FGFR1, FGFR1OP-FGFR1 or FGFR1-FGFR1OP may exhibit constitutive kinase activity and be responsible for the transforming activity.
Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell myeloproliferative disorder (MPD). Translocation t(8;9)(p12;q33) with CEP110. MPD is characterized by myeloid hyperplasia, eosinophilia and T-cell or B-cell lymphoblastic lymphoma. In general it progresses to acute myeloid leukemia. The fusion protein CEP110-FGFR1 is found in the cytoplasm, exhibits constitutive kinase activity and may be responsible for the transforming activity. -
序列相似性
Belongs to the protein kinase superfamily. Tyr protein kinase family. Fibroblast growth factor receptor subfamily.
Contains 3 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain. -
翻译后修饰
Binding of FGF1 and heparin promotes autophosphorylation on tyrosine residues and activation of the receptor. -
细胞定位
Membrane. Nucleus. Cytoplasm. Cytoplasmic vesicle - Information by UniProt
-
数据库链接
- Entrez Gene: 2260 Human
- Omim: 136350 Human
- SwissProt: P11362 Human
- Unigene: 264887 Human
-
别名
- Basic fibroblast growth factor receptor 1 antibody
- bFGF-R-1 antibody
- BFGFR antibody
see all
图片
-
Immunocytochemistry/ Immunofluorescence - Anti-FGFR1 antibody (ab10646)
Immunocytochemical immunofluorescence analysis of methanol fixed HeLa (Human epithelial cell line from cervix adenocarcinoma) cells labelling FGFR1 with ab10646 at a 1/100 dilution. Cells were fixed, then permeabilized. The secondary antibody used was a Goat Anti-Rabbit IgG, Cy3™ conjugate (red). Cells were counterstained with DAPI (blue) to stain nuclei.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGFR1 antibody (ab10646)Immunohistochemical analysis of formalin-fixed paraffin-embedded human umbilical cord sections, labeling FGFR1 with ab10646 at a 5 μg/mL concentration. The secondary used was a biotin-anti-Rabbit IgG Peroxidase.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGFR1 antibody (ab10646)Immunohistochemical analysis of formalin-fixed paraffin-embedded human umbilical cord sections, labeling FGFR1 with ab10646 at a 1/200 dilution.
Biotinylated secondary followed by avidin-HRP and AEC substrate, hematoxylin counterstain.
Antigen retrieval: 0.1% trypsin for 15 minutes at 37°C.
-
Immunocytochemistry/ Immunofluorescence - Anti-FGFR1 antibody (ab10646)Image from Wang YN et al., J Biol Chem. 2012 May 11;287(20):16869-79. Epub 2012 Mar 28. Fig 1.; doi: 10.1074/jbc.M111.314799; May 11, 2012 The Journal of Biological Chemistry, 287, 16869-16879.Immunofluorescence analysis of NIH/3T3 (Mouse embryo fibroblast cell line) cells, staining FGFR1 using ab10646.
Top row: Cells were either untreated (left) or treated with FGF2 (50 ng/ml) (right) for 60 minutes.
Bottom row: Cells were permeabilized with digitonin, and either untreated (left) or treated with FGF2 (50 ng/ml) (right) for 60 minutes. -
Western blot - Anti-FGFR1 antibody (ab10646)Lane 1 : Anti-FGFR1 antibody (ab10646) at 1/400 dilution
Lane 2 : Anti-FGFR1 antibody (ab10646) at 1/800 dilution
All lanes : Whole extract of 293T cells transfected wild type FGFR1
Secondary
All lanes : Goat-Anti-Rabbit IgG (whole molecule)-Alkaline Phosphatase antibody at 1/5000 dilutionLane 3: Negative control.
实验方案
数据表及文件
-
SDS download
-
Datasheet download
文献 (68)
ab10646 被引用在 68 文献中.
- Coetzee AS et al. Nuclear FGFR1 promotes pancreatic stellate cell-driven invasion through up-regulation of Neuregulin 1. Oncogene 42:491-500 (2023). PubMed: 36357571
- Gao Y et al. Localization of FGF21 Protein and Lipid Metabolism-Related Genes in Camels. Life (Basel) 13:N/A (2023). PubMed: 36836789
- Geng F et al. Knockdown of lncRNA NEAT1 suppresses proliferation and migration, and induces apoptosis of cervical cancer cells by regulating the miR‑377/FGFR1 axis. Mol Med Rep 25:N/A (2022). PubMed: 34779493
- Peng H & Ge P Long non‑coding RNA HCG18 facilitates the progression of laryngeal and hypopharyngeal squamous cell carcinoma by upregulating FGFR1 via miR‑133b. Mol Med Rep 25:N/A (2022). PubMed: 34878161
- Gonzalez-Ericsson PI et al. FGFR1 Antibody Validation and Characterization of FGFR1 Protein Expression in ER+ Breast Cancer. Appl Immunohistochem Mol Morphol 30:600-608 (2022). PubMed: 36083147